Louisiana, along with Arkansas and Alabama, filed two lawsuits challenging shield laws in New York, Massachusetts, and California that protect providers of mail-order abortion pills from legal action by states with abortion bans. Louisiana also sued the FDA over its policy allowing telehealth prescribing and mailing of mifepristone, citing safety concerns, as part of broader efforts to enforce its abortion restrictions post-Dobbs.
Read →Tag
Post Dobbs
Changes and debates following the U.S. Supreme Court Dobbs decision.
Women in states with post-Dobbs abortion bans, including Louisiana, face a 5.4% increase in annual out-of-pocket health insurance premium costs, with even higher increases for Black and Hispanic women. This rise is linked to insurers passing on costs associated with pregnancy and childbirth complications that have increased due to abortion restrictions in these states.
Read →By Alasdaire FleitasVolunteer Contributor, Save the Storks The Supreme Court cases, Danco Laboratories v Louisiana and GenBioPro v Louisiana, ruled that the manufacturers of the pill used for chemical abortions can continue to mail the drug mifepristone across state lines despite Louisiana’s abortion ban. This ruling comes on the heels of the infamous 2022 Supreme Court case Dobbs v Jackson Women’s Health […] The post Supreme Court Abortion Pill Ruling Expands Access to Mifepristone Nationwide appeared first on Save the Storks .
Read →Showing 3 of 3